http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 17 Feb 2026 18:56:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+Novo+Holdings+AS/26015858.html si-local-file:///var/storage/secattach/20260217/26015858.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+Novo+Holdings+AS/26015858.html Tue, 17 Feb 2026 18:56:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+Novo+Holdings+AS/26015858.html si-local-file:///var/storage/secattach/20260217/26015858.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+Novo+Holdings+AS/26015858.html Tue, 17 Feb 2026 18:56:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26013115.html si-local-file:///var/storage/secattach/20260217/26013115.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26013115.html Tue, 17 Feb 2026 16:16:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26013115.html si-local-file:///var/storage/secattach/20260217/26013115.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26013115.html Tue, 17 Feb 2026 16:16:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26012926.html si-local-file:///var/storage/secattach/20260217/26012926.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26012926.html Tue, 17 Feb 2026 16:13:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26012926.html si-local-file:///var/storage/secattach/20260217/26012926.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26012926.html Tue, 17 Feb 2026 16:13:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26010250.html si-local-file:///var/storage/secattach/20260217/26010250.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26010250.html Tue, 17 Feb 2026 12:42:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26010250.html si-local-file:///var/storage/secattach/20260217/26010250.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26010250.html Tue, 17 Feb 2026 12:42:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+GOLDMAN+SACHS+GROUP+INC/25968046.html si-local-file:///var/storage/secattach/20260209/25968046.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+GOLDMAN+SACHS+GROUP+INC/25968046.html Mon, 09 Feb 2026 16:06:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+GOLDMAN+SACHS+GROUP+INC/25968046.html si-local-file:///var/storage/secattach/20260209/25968046.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++4D+Molecular+Therapeutic+++++++++++++++Filed+by%3A+GOLDMAN+SACHS+GROUP+INC/25968046.html Mon, 09 Feb 2026 16:06:00 -0500 FDMT O.47011821 http://www.streetinsider.com/New+Coverage/Barclays+Starts+4D+Molecular+Therapeutics+%28FDMT%29+at+Overweight/25901204.html <p>Barclays analyst Eliana Merle initiates coverage on 4D Molecular Therapeutics (NASDAQ: FDMT) with a Overweight rating and a price target of $33.00.</p> <p>For an analyst ratings summary and ratings history on 4D Molecular Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=FDMT">click here</a>. For more ratings news on 4D Molecular Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=FDMT&amp;type=analyst">click here</a>.</p> <p>Shares of 4D Molecular Therapeutics closed at $7.97 yesterday.</p> http://www.streetinsider.com/New+Coverage/Barclays+Starts+4D+Molecular+Therapeutics+%28FDMT%29+at+Overweight/25901204.html Tue, 27 Jan 2026 16:33:26 -0500 FDMT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++4D+Molecular+Therapeutic++For%3A+Jan+22/25893306.html si-local-file:///var/storage/secattach/20260126/25893306.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++4D+Molecular+Therapeutic++For%3A+Jan+22/25893306.html Mon, 26 Jan 2026 16:06:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++4D+Molecular+Therapeutic++For%3A+Jan+22/25893306.html si-local-file:///var/storage/secattach/20260126/25893306.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++4D+Molecular+Therapeutic++For%3A+Jan+22/25893306.html Mon, 26 Jan 2026 16:06:00 -0500 FDMT O.47011821 http://www.streetinsider.com/Press+Releases/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html <p align="left">EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global http://www.streetinsider.com/Press+Releases/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html Sat, 17 Jan 2026 08:00:00 -0500 A.06822034 FDMT O.20026344 O.47011821 http://www.streetinsider.com/Press+Releases/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html <p align="left">EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global http://www.streetinsider.com/Press+Releases/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html Sat, 17 Jan 2026 08:00:00 -0500 A.06822034 FDMT O.20026344 O.47011821 http://www.streetinsider.com/Press+Releases/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html <p align="left">EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global http://www.streetinsider.com/Press+Releases/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html Sat, 17 Jan 2026 08:00:00 -0500 A.06822034 FDMT O.20026344 O.47011821 http://www.streetinsider.com/Press+Releases/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html <p align="left">EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global http://www.streetinsider.com/Press+Releases/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html Sat, 17 Jan 2026 08:00:00 -0500 A.06822034 FDMT O.20026344 O.47011821 http://www.streetinsider.com/Globe+Newswire/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html <p align="left">EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global http://www.streetinsider.com/Globe+Newswire/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html Sat, 17 Jan 2026 08:00:00 -0500 A.06822034 FDMT O.20026344 O.47011821 http://www.streetinsider.com/Globe+Newswire/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html <p align="left">EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global http://www.streetinsider.com/Globe+Newswire/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html Sat, 17 Jan 2026 08:00:00 -0500 A.06822034 FDMT O.20026344 O.47011821 http://www.streetinsider.com/Globe+Newswire/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html <p align="left">EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global http://www.streetinsider.com/Globe+Newswire/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html Sat, 17 Jan 2026 08:00:00 -0500 A.06822034 FDMT O.20026344 O.47011821 http://www.streetinsider.com/Globe+Newswire/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html <p align="left">EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global http://www.streetinsider.com/Globe+Newswire/4DMT+Announces+New+Employment+Inducement+Grants/25861654.html Sat, 17 Jan 2026 08:00:00 -0500 A.06822034 FDMT O.20026344 O.47011821 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++4D+Molecular+Therapeutic++For%3A+Jan+05++Filed+by%3A+SBLENDORIO+GLENN/25821709.html si-local-file:///var/storage/secattach/20260107/25821709.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++4D+Molecular+Therapeutic++For%3A+Jan+05++Filed+by%3A+SBLENDORIO+GLENN/25821709.html Wed, 07 Jan 2026 21:13:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++4D+Molecular+Therapeutic++For%3A+Jan+05++Filed+by%3A+SBLENDORIO+GLENN/25821709.html si-local-file:///var/storage/secattach/20260107/25821709.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++4D+Molecular+Therapeutic++For%3A+Jan+05++Filed+by%3A+SBLENDORIO+GLENN/25821709.html Wed, 07 Jan 2026 21:13:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++4D+Molecular+Therapeutic++For%3A+Jan+05++Filed+by%3A+SBLENDORIO+GLENN/25821707.html si-local-file:///var/storage/secattach/20260107/25821707.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++4D+Molecular+Therapeutic++For%3A+Jan+05++Filed+by%3A+SBLENDORIO+GLENN/25821707.html Wed, 07 Jan 2026 21:10:00 -0500 FDMT O.47011821 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++4D+Molecular+Therapeutic++For%3A+Jan+05++Filed+by%3A+SBLENDORIO+GLENN/25821707.html si-local-file:///var/storage/secattach/20260107/25821707.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++4D+Molecular+Therapeutic++For%3A+Jan+05++Filed+by%3A+SBLENDORIO+GLENN/25821707.html Wed, 07 Jan 2026 21:10:00 -0500 FDMT O.47011821